Class & Mechanism — Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. It acts on both GIP and GLP-1 receptors, enhancing its effects on blood glucose control and weight reduction compared to selective GLP-1 receptor agonists. [22]
Research-documented benefits —
– Tirzepatide was found to be slightly better than semaglutide at lowering blood sugar levels and aiding weight loss. [22]
General-knowledge benefits —
– As a dual GIP and GLP-1 receptor agonist, tirzepatide may offer improved glycemic control and weight reduction compared to selective GLP-1 receptor agonists. [22]
Typical injectable protocol — The exact dosing protocol for tirzepatide is not specified in the provided excerpts, but it is generally administered subcutaneously. [22]
Key risks / contraindications — The excerpts do not specify risks or contraindications for tirzepatide, but common side effects for this class of medications include gastrointestinal issues. [22]
Bottom line — Tirzepatide is a novel dual GIP and GLP-1 receptor agonist with potential advantages in glycemic control and weight management over selective GLP-1 receptor agonists.
References
- Antimicrobial Peptides and Human Disease
- Basal Insulin Glargine 100 U_mL Versus 300 U_mL in Type 2 Diabetes
- GLP-1 and the kidney_ from physiology to pharmacology and outcomes in diabetes
- Growth Hormone Secretagogues in Clinical Practice
- Handbook of Biologically Active Peptides
- Human trials exploring anti-aging medicines — Guarente, Leonard (author)
- Incretin-Based Therapies for Type 2 Diabetes
- Kosmetik für Ärzte und Apotheker
- Nutrition in Mental Health_ A Handbook
- Peptide Therapeutics_ Design and Development
- Peptides_ Chemistry and Biology, 2nd Edition
- Platelets
- Prodrugs_ Challenges and Rewards
- Super Agers An Evidence-Based Approach to Longevity — Eric Topol
- The AI Revolution in Medicine_ GPT-4 and Beyond
- The discovery and development of liraglutide and semaglutide